Sökresultat - Issa, Samar

Carbazole scaffolds in cancer therapy: a review from 2012 to 2018 av Issa, Samar, Prandina, Anthony, Bedel, Nicolas, Rongved, Pål, Yous, Saïd, Le Borgne, Marc, Bouaziz, Zouhair

Hämta fulltext Hämta fulltext Hämta fulltext

Regulation of microRNAs in Cancer Metastasis av Bouyssou, Juliette M.C., Manier, Salomon, Huynh, Daisy, Issa, Samar, Roccaro, Aldo M., Ghobrial, Irene M.

Hämta fulltext Hämta fulltext Hämta fulltext

MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma av van der Meulen, Matthijs, Dirven, Linda, Bakunina, Katerina, van den Bent, Martin J., Issa, Samar, Doorduijn, Jeanette K., Bromberg, Jacoline E. C.

Hämta fulltext Hämta fulltext Hämta fulltext

NCOG-05. IMPACT OF ADDITIONAL RITUXIMAB TO STANDARD THERAPY ON COGNITIVE PERFORMANCES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS av van der Meulen, Matthijs, Dirven, Linda, Habets, Esther, Bakunina, Katerina, Taphoorn, Martin, van den Bent, Martin, Issa, Samar, Doorduijn, Jeanette K, Bromberg, Jacoline E C

Hämta fulltext Hämta fulltext

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation – an International Primary Central Nervous System Lymphoma Study Group project av Bromberg, Jacoline E., Doorduijn, Jeanette K., Illerhaus, Gerald, Jahnke, Kristoph, Korfel, Agniezka, Fischer, Lars, Fritsch, Kristina, Kuittinen, Outti, Issa, Samar, van Montfort, Cees, van den Bent, Martin J.

Hämta fulltext Hämta fulltext Hämta fulltext

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY P... av Soussain, Carole, Grommes, Christian, Issa, Samar, Ward, Renee, Peterson, Caryn, Cravets, Matt, Mathias, Anita, Sosa, Judith, Kirby, Brian, Ding, Zhaoqing, Yusuf, Isharat, Rose, Mark, Steinberg, Marcos, Tun, Han W

Hämta fulltext Hämta fulltext

Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI av Wieduwilt, Matthew J., Valles, Francisco, Issa, Samar, Behler, Caroline M., Hwang, James, McDermott, Michael, Treseler, Patrick, O’Brien, Joan, Shuman, Marc A., Cha, Soonmee, Damon, Lloyd E., Rubenstein, James L.

Hämta fulltext Hämta fulltext Hämta fulltext

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Fo... av Flinn, Ian W., van der Jagt, Richard, Kahl, Brad, Wood, Peter, Hawkins, Tim, MacDonald, David, Simpson, David, Kolibaba, Kathryn, Issa, Samar, Chang, Julie, Trotman, Judith, Hallman, Doreen, Chen, Ling, Burke, John M.

Hämta fulltext Hämta fulltext Hämta fulltext

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study av Flinn, Ian W., van der Jagt, Richard, Kahl, Brad S., Wood, Peter, Hawkins, Tim E., MacDonald, David, Hertzberg, Mark, Kwan, Yiu-Lam, Simpson, David, Craig, Michael, Kolibaba, Kathryn, Issa, Samar, Clementi, Regina, Hallman, Doreen M., Munteanu, Mihaela, Chen, Ling, Burke, John M.

Hämta fulltext Hämta fulltext Hämta fulltext

Extent of radiological response does not reflect survival in primary central nervous system lymphoma av van der Meulen, Matthijs, Postma, Alida A, Smits, Marion, Bakunina, Katerina, Minnema, Monique C, Seute, Tatjana, Cull, Gavin, Enting, Roelien H, van der Poel, Marjolein, Stevens, Wendy B C, Brandsma, Dieta, Beeker, Aart, Doorduijn, Jeanette K, Issa, Samar, van den Bent, Martin J, Bromberg, Jacoline E C

Hämta fulltext Hämta fulltext Hämta fulltext

Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial av van der Meulen, Matthijs, Dirven, Linda, Habets, Esther J J, Bakunina, Katerina, Smits, Marion, Achterberg, Hakim C, Seute, Tatjana, Cull, Gavin, Schouten, Harry, Zijlstra, Josée M, Brandsma, Dieta, Enting, Roelien H, Beijert, Max, Taphoorn, Martin J B, van den Bent, Martin J, Issa, Samar, Doorduijn, Jeanette K, Bromberg, Jacoline E C

Hämta fulltext Hämta fulltext Hämta fulltext

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets av Yeung, David T., Osborn, Michael P., White, Deborah L., Branford, Susan, Braley, Jodi, Herschtal, Alan, Kornhauser, Michael, Issa, Samar, Hiwase, Devendra K., Hertzberg, Mark, Schwarer, Anthony P., Filshie, Robin, Arthur, Christopher K., Kwan, Yiu Lam, Trotman, Judith, Forsyth, Cecily J., Taper, John, Ross, David M., Beresford, Jennifer, Tam, Constantine, Mills, Anthony K., Grigg, Andrew P., Hughes, Timothy P.

Hämta fulltext Hämta fulltext Hämta fulltext